Preprint: GPNMB and glycosphingolipid measurements in cerebrospinal fluid and plasma from Parkinson's disease patients in the BioFind cohort
WHY IT MATTERS
If GPNMB and glycosphingolipid measurements prove reliable, they could become blood tests that help diagnose Parkinson's disease earlier, before major symptoms appear, potentially allowing earlier treatment.
Researchers studied two proteins called GPNMB and glycosphingolipids in blood and spinal fluid samples from Parkinson's disease patients. These proteins may be important markers that show when the brain's waste-disposal system (called lysosomes) isn't working properly in Parkinson's disease. This early-stage research could help doctors better understand and diagnose Parkinson's disease in the future.
GPNMB and glycosphingolipid measurements in cerebrospinal fluid and plasma from Parkinson's disease patients in the BioFind cohort Authors: Fernandez-Suarez, M. E. et al. Server: bioRxiv Category: neuroscience Abstract: BackgroundParkinsons disease (PD) is a prevalent neurodegenerative disorder characterized by progressive motor dysfunction and broad cellular impairment, including significant disruptions in lysosomal function, lipid metabolism, and intracellular trafficking. Glycosphingolipids (GSLs), critical for various cellular processes, depend on effective lysosomal degradation. Aberrant GSL metabolism has been linked to PD pathology, and glycoprotein non-metastatic melanoma protein B (GPNMB) has emerged as a biomarker associated with lysosomal dysfunction and lipid imbalance in PD. ObjectivesTo assess